Innate Pharma (IPHA) Free Cash Flow (2020 - 2024)
Historic Free Cash Flow for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$7.4 million.
- Innate Pharma's Free Cash Flow rose 7896.46% to -$7.4 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$42.4 million, marking a year-over-year increase of 2230.68%. This contributed to the annual value of -$7.9 million for FY2024, which is 7784.51% up from last year.
- Latest data reveals that Innate Pharma reported Free Cash Flow of -$7.4 million as of Q4 2024, which was up 7896.46% from -$35.0 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Free Cash Flow registered a high of -$7.4 million during Q4 2024, and its lowest value of -$66.9 million during Q4 2021.
- In the last 5 years, Innate Pharma's Free Cash Flow had a median value of -$35.0 million in 2023 and averaged -$38.1 million.
- In the last 5 years, Innate Pharma's Free Cash Flow plummeted by 7925.51% in 2023 and then soared by 7896.46% in 2024.
- Over the past 5 years, Innate Pharma's Free Cash Flow (Quarter) stood at -$61.7 million in 2020, then dropped by 8.35% to -$66.9 million in 2021, then surged by 70.78% to -$19.5 million in 2022, then tumbled by 79.26% to -$35.0 million in 2023, then skyrocketed by 78.96% to -$7.4 million in 2024.
- Its Free Cash Flow stands at -$7.4 million for Q4 2024, versus -$35.0 million for Q4 2023 and -$19.5 million for Q4 2022.